Melanotan I (MT-1) × PurgoLabs peptides — lab test, lot PL-002, March 2026
COA 2603110037 matches freedomdiagnosticstesting.com's public record. So this test doesn't rest on our review alone — the lab confirms it too.
Purg2603110037Test results
This is a purity and identity analysis. Sterility, endotoxins, and heavy metals were not screened — a high purity figure says nothing about those.
About this test
Label 10 mg · Lab measured 13.54 mg
135% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 3.4 mg using the measured mass, against 2.5 mg on the label — 35% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
| Report number | 2603110037 |
|---|---|
| Portal lookup | ✓ Lab-verified |
| Checked | 8 Aug 2026date taken from the record, not from a logged check |
| Checked by | Peptigrity staff, against the lab's portal |
| PDF vs portal | freedomdiagnosticstesting.com's portal shows validity only |
| Weight | Counts as one lab test |
Independent HPLC purity analysis of Melanotan I (MT-1) from PurgoLabs peptides, performed by freedomdiagnosticstesting.com on March 12, 2026. Reported purity: 99.812%. Net content: 13.54 mg against 10 mg labeled (135% of label). Tested content exceeds the labeled amount by 35%. Batch PL-002. Sample source: shop-provided. Certificate of analysis attached.
Certificate of analysis
Other lots of Melanotan I (MT-1) from PurgoLabs peptides
| Lot | Tested | Lab | Purity | vs label | Status |
|---|---|---|---|---|---|
| PL-MT1-03 | 12 May 2026 | freedomdiagnosticstesting.com | 99.63% | 114% | ✓ Lab-verified |
| PS03-MT12 | 11 Mar 2026 | freedomdiagnosticstesting.com | 99.709% | 143% | ✓ Lab-verified |
Batches this shop has published a certificate for, newest first. A lot whose printed value cannot identify a batch is not listed.
Have you tested this peptide?
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion